[1] Geneva: World Health Organization; 2011.Global prevalence and incidence of selected curable sexually transmitted diseases: Overview and estimates.[2] 郑冰洁,尹跃平.泌尿生殖道沙眼衣原体感染的流行病学进展[J].国际皮肤性病学杂志,2011,3:183-186.[3] Malhotra M,Sood S,Mukherjee A,et al.Genital Chlamydia trachomatis: an update[J].Indian J Med Res,2013,138(3):303-316.[4] Centers for Disease Control and Prevention.Recommendations for the laboratory-based detection of Chlamydia trachomatis and Neisseria gonorrhoeae,2014[J].MMWR Recommendations and Reports,2014,63( RR-2):1-14.[5] Centers for Disease Control and Prevention.Sexually transmitted diseases treatment guidelines,2010[J].MMWR Recommendations and Reports,2010,59(RR-12) :1-110.[6] 刘朝晖,薛凤霞.黏液脓性宫颈炎的诊断和治疗[J].中国实用妇科与产科杂志,2012,4:241-242.[7] Mourad A,Sweet RL,Sugg N,et al.Relative resistance to erythromycin in Chlamydia trachomatis[J].Antimicrob Agents Chemother,1980,18(5):696-698.[8] Jones RB,Van der Pol B,Johnson RB.Susceptibility of Chlamydia trachomatis to trovafloxacin[J].J Antimicrob Chemother,1997,39(Suppl B):63-65.[9] Somani J,Bhullar VB,Workowski KA,et al.Multiple drug-resistant Chlamydia trachomatis associated with clinical treatment failure[J].J Infect Dis,2000,181(4):1421-1427.[10] Gomberg MA.Combined treatment of persisting urogenital chlamydia infection with sumamed and interferon alfa [J].Antibiot Khimioter,2002,47(5):12-15.[11] American College of Obstetricians and Gynecologists.ACOG Practice Bulletin No.121.Long-acting reversible contraception: Implants and intrauterine devices[J].Obstet Gynecol,2011,118(1):184-196.[12] Caddy S,Yudin MH,Hakim J,et al.Best practices to minimize risk of infection with intrauterine device Insertion[J].J Obstet Gynaecol Can,2014,36(3):266-276.[13] Hocking JS,Guy R,Walker J,et al.Advances in sampling and screening for chlamydia[J].Future Microbiol,2013,8(3):367-386.